Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb 21;18(1):78.
doi: 10.1186/s13063-017-1825-7.

Sample size considerations for trials using cerebral white matter hyperintensity progression as an intermediate outcome at 1 year after mild stroke: results of a prospective cohort study

Francesca M Chappell  1 , Maria Del Carmen Valdés Hernández  1 , Stephen D Makin  1 , Kirsten Shuler  1 , Eleni Sakka  1 , Martin S Dennis  1 , Paul A Armitage  2 , Susana Muñoz Maniega  1 , Joanna M Wardlaw  3
Affiliations

Sample size considerations for trials using cerebral white matter hyperintensity progression as an intermediate outcome at 1 year after mild stroke: results of a prospective cohort study

Francesca M Chappell et al. Trials. .

Abstract

Background: White matter hyperintensities (WMHs) are commonly seen on in brain imaging and are associated with stroke and cognitive decline. Therefore, they may provide a relevant intermediate outcome in clinical trials. WMH can be measured as a volume or visually on the Fazekas scale. We investigated predictors of WMH progression and design of efficient studies using WMH volume and Fazekas score as an intermediate outcome.

Methods: We prospectively recruited 264 patients with mild ischaemic stroke and measured WMH volume, Fazekas score, age and cardiovascular risk factors at baseline and 1 year. We modelled predictors of WMH burden at 1 year and used the results in sample size calculations for hypothetical randomised controlled trials with different analysis plans and lengths of follow-up.

Results: Follow-up WMH volume was predicted by baseline WMH: a 0.73-ml (95% CI 0.65-0.80, p < 0.0001) increase per 1-ml baseline volume increment, and a 2.93-ml increase (95% CI 1.76-4.10, p < 0.0001) per point on the Fazekas scale. Using a mean difference of 1 ml in WMH volume between treatment groups, 80% power and 5% alpha, adjusting for all predictors and 2-year follow-up produced the smallest sample size (n = 642). Other study designs produced samples sizes from 2054 to 21,270. Sample size calculations using Fazekas score as an outcome with the same power and alpha, as well as an OR corresponding to a 1-ml difference, were sensitive to assumptions and ranged from 2504 to 18,886.

Conclusions: Baseline WMH volume and Fazekas score predicted follow-up WMH volume. Study size was smallest using volumes and longer-term follow-up, but this must be balanced against resources required to measure volumes versus Fazekas scores, bias due to dropout and scanner drift. Samples sizes based on Fazekas scores may be best estimated with simulation studies.

Keywords: Sample size calculation; Study design; White matter hyperintensities.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
a Baseline white matter hyperintensity (WMH) volume versus 1-year follow-up WMH volume. b Each line represents the change for an individual patient
Fig. 2
Fig. 2
Change in white matter hyperintensity (WMH) (follow-up minus baseline) versus blood pressure
See this image and copyright information in PMC

References

    1. Kim TW, Kim YH, Kim KH, Chang WH. White matter hyperintensities and cognitive dysfunction in patients with infratentorial stroke. Ann Rehabil Med. 2014;38(5):620–7. doi: 10.5535/arm.2014.38.5.620. - DOI - PMC - PubMed
    1. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke. 2003;34(5):1126–9. doi: 10.1161/01.STR.0000068408.82115.D2. - DOI - PubMed
    1. Kim YJ, Kwon HK, Lee JM, Kim YJ, Kim HJ, Jung NY, et al. White matter microstructural changes in pure Alzheimer’s disease and subcortical vascular dementia. Eur J Neurol. 2015;22(4):709–16. doi: 10.1111/ene.12645. - DOI - PubMed
    1. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010;341:c3666. doi: 10.1136/bmj.c3666. - DOI - PMC - PubMed
    1. Sachdev PS, Wen W, Christensen H, Jorm AF. White matter hyperintensities are related to physical disability and poor motor function. J Neurol Neurosurg Psychiatry. 2005;76(3):362–7. doi: 10.1136/jnnp.2004.042945. - DOI - PMC - PubMed

Publication types

MeSH terms